Literature DB >> 24354448

Effectiveness and safety of rapid clozapine titration in schizophrenia.

P Ifteni1, J Nielsen, V Burtea, C U Correll, J M Kane, P Manu.   

Abstract

OBJECTIVE: Clinical guidelines recommend slow clozapine dose titration in order to decrease the risk of seizures and hypotension. The recommendation may delay adequate control of severe psychotic symptoms. We evaluated the safety and effectiveness of rapid clozapine titration in patients who had been previously exposed to the drug and in patients who received clozapine for the first time after failing to respond to other antipsychotics.
METHOD: Analysis of hospital course of a consecutive cohort of schizophrenia patients (N = 111) who received 25-100 mg of clozapine as needed every 6 h the first treatment day, followed by upward adjustments of 25-100 mg/day.
RESULTS: Symptom control was obtained with an average dose of 353 ± 174 mg/day after 4.1 ± 3.1 days in the 73 patients previously treated with clozapine. For the 38 patients initially started on other antipsychotics, the average clozapine dose required for symptom control (409 ± 188 mg/day) was reached after 7.1 ± 4.8 days. None of the patients had seizures, severe hypotension or other major adverse reactions.
CONCLUSION: In this naturalistic cohort study rapid clozapine titration appeared safe and effective for the treatment of schizophrenia. The results justify controlled clinical trials of this treatment method.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clozapine; rapid titration; schizophrenia; symptom control

Mesh:

Substances:

Year:  2013        PMID: 24354448     DOI: 10.1111/acps.12241

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  12 in total

1.  Rapid Clozapine Titration in Patients with Treatment Refractory Schizophrenia.

Authors:  Cana Aksoy Poyraz; Armağan Özdemir; Nazife Gamze Usta Sağlam; Şenol Turan; Burç Çağrı Poyraz; Nesrin Tomruk; Alaattin Duran
Journal:  Psychiatr Q       Date:  2016-06

2.  Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study.

Authors:  Masaru Tsukahara; Ryuhei So; Yuji Yada; Masafumi Kodama; Yoshiki Kishi
Journal:  Psychiatr Q       Date:  2020-09-05

Review 3.  Seizure associated with clozapine: incidence, etiology, and management.

Authors:  Andrew M Williams; Susie H Park
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 4.  Neurology issues in schizophrenia.

Authors:  Katharina Hüfner; Beatrice Frajo-Apor; Alex Hofer
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

5.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 6.  Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series.

Authors:  Cana Aksoy Poyraz; Şenol Turan; Ömer Faruk Demirel; Nazife Gamze Usta Sağlam; Nazım Yıldız; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 7.  Systematic Review of Clozapine Cardiotoxicity.

Authors:  Martina Curto; Nicoletta Girardi; Luana Lionetto; Giuseppino M Ciavarella; Stefano Ferracuti; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-07       Impact factor: 5.285

8.  Risks and Benefits of Rapid Clozapine Titration.

Authors:  Jeannie D Lochhead; Michele A Nelson; Alan L Schneider
Journal:  Ment Illn       Date:  2016-05-18

Review 9.  Review of withdrawal catatonia: what does this reveal about clozapine?

Authors:  Matthew Lander; Tarun Bastiampillai; Jitender Sareen
Journal:  Transl Psychiatry       Date:  2018-07-31       Impact factor: 6.222

Review 10.  Use of Clozapine in the General Hospital.

Authors:  Feras Ali Mustafa
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.